⚠ Evidence note: Most trends in this area rest on anecdote and mechanism; where real evidence exists it is usually for narrower claims than the trend makes.
Gene Therapy for Muscle Aging
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-10-03 — Myostatin inhibitors and the paradox of larger but weaker muscles: cross-connection with myostatin-inhibitors-longevity: Both target sarcopenia via muscle-mass pathways; the mass-vs-strength dissociation Attia flags is a shared evaluative problem for any muscle-enlarging intervention, including gene-therapy approaches. (novelty: 3)
- 2026-10-07 — KHL Foundation Reports the Likely First Human Partial Epigenetic Reprogramming Treatments: cross-connection with partial-epigenetic-reprogramming: Both are AAV-delivered longevity gene therapies moving from animal data toward human use via a mix of formal trials and offshore self-experimentation. (novelty: 4)
- 2026-07-13 — CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy: CALM-AF-AI Phase 1/2a open-label trial launched evaluating intramuscular AAV9-follistatin alone or combined with a VEGF-encoding angiogenesis plasmid for safety and preliminary muscle mass/performance effects in age-related muscle loss — first-in-class dual gene-therapy design, no efficacy data yet (human-rct, early Phase 1/2a). [human-rct] (novelty: 4)
Open questions
Related
Contributing findings
CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy
13-jul-2026
novelty 4
per-area 4
strengthens